{
    "id": "63f043e4f36125a426000023",
    "question": "Is Baricitinib effective for Alopecia Areata?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "A",
    "predict": "{ \"step_by_step_thinking\": \"To determine if Baricitinib is effective for Alopecia Areata, we need to look for any information related to Baricitinib and its effects on alopecia. However, Baricitinib is not mentioned in the provided documents. The documents do mention other JAK inhibitors, such as Tofacitinib, and their effects on various conditions, including psoriasis and rheumatoid arthritis. However, there is no specific information on Baricitinib and its effectiveness for Alopecia Areata. Therefore, we cannot conclude that Baricitinib is effective for Alopecia Areata based on the provided documents. In fact, the documents do not mention Baricitinib at all. However, it is worth noting that the documents do mention other treatments for alopecia, such as minoxidil, finasteride, and spironolactone, as well as the importance of ruling out underlying metabolic causes, such as hypothyroidism, and treating any underlying conditions that may be contributing to the alopecia.\", \"answer_choice\": \"B\" }",
    "snippets": [
        {
            "id": "InternalMed_Harrison_4055",
            "title": "InternalMed_Harrison",
            "content": "Oral griseofulvin or terbinafine plus 2.5% selenium sulfide or ketoconazole shampoo; examine family members Discontinuation of offending hair style or chemical treatments; diagnosis of trichotillomania may require observation of shaved hairs (for growth) or biopsy, possibly followed by psychotherapy aTo date, Food and Drug Administration\u2013approved for men. bScarring alopecia can occur at sites of kerions. cMay also be scarring, especially late-stage traction alopecia. CAuSES of figuRATE SKin LESionS I. Primary cutaneous disorders A. Tinea B. Urticaria (primary in \u226590% of patients) C. Granuloma annulare D. Erythema annulare centrifugum E. Psoriasis II. A. 1. Erythema migrans (CDC case definition is \u22655 cm in diameter) 2. Urticaria (\u226410% of patients) 3. 4. 5. 6. B. Nonmigratory 1. 2. 3. 4. Cutaneous T cell lymphoma (especially mycosis fungoides) aMigratory erythema with erosions; favors lower extremities and girdle area."
        },
        {
            "id": "Pharmacology_Katzung_4037",
            "title": "Pharmacology_Katzung",
            "content": "3. Indications: Tofacitinib was originally developed to prevent solid organ allograft rejection. It has also been tested for the treatment of inflammatory bowel disease, spondyloarthritis, psoriasis, and dry eyes. To date, tofacitinib is approved in the United States for the treatment of adult patients with moderately to severely active RA who have failed or are intolerant to methotrexate. It is not approved in Europe for this indication. It can be used as a monotherapy or in combination with other csDMARDs, including methotrexate. Ongoing studies are evaluating its role in other rheumatic diseases such as PsA, psoriasis, and JIA. 4."
        },
        {
            "id": "Pharmacology_Katzung_2003",
            "title": "Pharmacology_Katzung",
            "content": "Bimatoprost is FDA approved for treatment of eyelash hypotrichosis and has shown efficacy in enhancing eyelash growth after chemotherapy. The drug is applied in a 0.03% solution to the skin at the base of the upper lashes. A common but minor adverse effect is darkening of eyelid skin due to increased melanin production that is reversible with discontinuation. Recent trials have also demonstrated efficacy in eyebrow hypotrichosis, and emerging studies have suggested that this drug may have utility for treating alopecia."
        },
        {
            "id": "InternalMed_Harrison_4046",
            "title": "InternalMed_Harrison",
            "content": "erythroderma where there is no apparent cause Exposure to various drugs can also cause diffuse hair loss, (idiopathic), longitudinal evaluation is mandatory to monitor for the usually by inducing a telogen effluvium. An exception is the anagen possible development of CTCL. There have been isolated case reports effluvium observed with antimitotic agents such as daunorubicin. of erythroderma secondary to some solid tumors\u2014lung, liver, prostate, Alopecia is a side effect of the following drugs: warfarin, heparin, thyroid, and colon\u2014but it is primarily during a late stage of the disease. propylthiouracil, carbimazole, isotretinoin, acitretin, lithium, beta blockers, interferons, colchicine, and amphetamines. Fortunately, spontaneous regrowth usually follows discontinuation of the offend- ing agent. (Table 72-4) The two major forms of alopecia are scarring and non-Less commonly, nonscarring alopecia is associated with lupus eryscarring. Scarring alopecia is associated with fibrosis,"
        },
        {
            "id": "Pharmacology_Katzung_4002",
            "title": "Pharmacology_Katzung",
            "content": "4. Adverse Effects: Nausea and mucosal ulcers are the most common toxicities. Additionally, many other side effects such as leukopenia, anemia, stomatitis, GI ulcerations, and alopecia are probably the result of inhibiting cellular proliferation. Progressive dose-related hepatotoxicity in the form of enzyme elevation occurs frequently, but cirrhosis is rare (<1%). Liver toxicity is not related to serum methotrexate concentrations. A rare hypersensitivity-like lung reaction with acute shortness of breath has been documented, as have pseudo-lymphomatous reactions. The incidence of GI and liver function test abnormalities can be reduced by the use of leucovorin 24 hours after each weekly dose or by the use of folic acid, although this may decrease the efficacy of the methotrexate by about 10%. This drug is contraindicated in pregnancy. 1."
        },
        {
            "id": "InternalMed_Harrison_4054",
            "title": "InternalMed_Harrison",
            "content": "Increased levels of circulating androgens (ovarian or adrenal source in women) The germinative zones of the hair follicles are surrounded by T lymphocytes Occasional associated diseases: hyperthyroidism, hypothyroidism, vitiligo, Down syndrome Invasion of hairs by dermatophytes, most commonly Trichophyton tonsurans Traction with curlers, rubber bands, braiding Exposure to heat or chemicals (e.g., hair straighteners) Mechanical pulling (trichotillomania) Observation; discontinue any drugs that have alopecia as a side effect; must exclude underlying metabolic causes, e.g., hypothyroidism, hyperthyroidism If no evidence of hyperandrogenemia, then topical minoxidil; finasteridea; spironolactone (women); hair transplant Oral griseofulvin or terbinafine plus 2.5% selenium sulfide or ketoconazole shampoo; examine family members"
        },
        {
            "id": "InternalMed_Harrison_4286",
            "title": "InternalMed_Harrison",
            "content": "FIguRE 74-1 Pseudoporphyria due to nonsteroidal anti-inflammatory drugs. FIguRE 74-2 Warfarin necrosis. 380 of the responsible agent. The prevalence and severity of alopecia depend on the drug as well as on an individual\u2019s predisposition. A considerable number of drugs have been reported to induce hair loss. These include antineoplastic agents (alkylating agents, bleomycin, vinca alkaloids, platinum compounds), anticonvulsants (carbamazepine, valproate), antihypertensive drugs (beta blockers), antidepressants, antithyroid drugs, IFNs (especially IFN-\u03b1), oral contraceptives, and cholesterol-lowering agents."
        },
        {
            "id": "InternalMed_Harrison_4047",
            "title": "InternalMed_Harrison",
            "content": "ing agent. (Table 72-4) The two major forms of alopecia are scarring and non-Less commonly, nonscarring alopecia is associated with lupus eryscarring. Scarring alopecia is associated with fibrosis, inflammation, thematosus and secondary syphilis. In systemic lupus there are two and loss of hair follicles. A smooth scalp with a decreased number of forms of alopecia\u2014one is scarring secondary to discoid lesions (see follicular openings is usually observed clinically, but in some patients, below), and the other is nonscarring. The latter form coincides with the changes are seen only in biopsy specimens from affected areas. In flares of systemic disease and may involve the entire scalp or just nonscarring alopecia, the hair shafts are absent or miniaturized, but the the frontal scalp, with the appearance of multiple short hairs (\u201clupus hair follicles are preserved, explaining the reversible nature of nonscar-hairs\u201d) as a sign of initial regrowth. Scattered, poorly circumscribed ring"
        },
        {
            "id": "Pharmacology_Katzung_3987",
            "title": "Pharmacology_Katzung",
            "content": "placebo than in those treated with abatacept over 1 year. Abatacept has been tested in other rheumatic diseases like SLE, primary Sj\u00f6gren\u2019s syndrome, type 1 diabetes, inflammatory bowel disease, and psoriasis vulgaris, but the most beneficial effects were seen in psoriatic arthritis (PsA) patients."
        },
        {
            "id": "InternalMed_Harrison_4048",
            "title": "InternalMed_Harrison",
            "content": "the appearance of multiple short hairs (\u201clupus hair follicles are preserved, explaining the reversible nature of nonscar-hairs\u201d) as a sign of initial regrowth. Scattered, poorly circumscribed ring alopecia. patches of alopecia with a \u201cmoth-eaten\u201d appearance are a manifestation"
        },
        {
            "id": "Pharmacology_Katzung_5476",
            "title": "Pharmacology_Katzung",
            "content": "The adverse effects of interferon alfa include a flu-like syndrome (ie, headache, fevers, chills, myalgias, and malaise) that occurs within 6 hours after dosing in more than 30% of patients; it tends to resolve upon continued administration. Transient hepatic enzyme elevations may occur in the first 8\u201312 weeks of therapy and appear to be more common in responders. Potential adverse effects during chronic therapy include neurotoxicities (mood disorders, depression, somnolence, confusion, seizures), myelosuppression, profound fatigue, weight loss, rash, cough, myalgia, alopecia, tinnitus, reversible hearing loss, retinopathy, pneumonitis, and possibly cardiotoxicity. Induction of autoantibodies may occur, causing exacerbation or unmasking of autoimmune disease (particularly thyroiditis)."
        },
        {
            "id": "Pharmacology_Katzung_6967",
            "title": "Pharmacology_Katzung",
            "content": "At higher dosage, methotrexate may cause bone marrow depression, megaloblastic anemia, alopecia, and mucositis. At the doses used in the treatment of IBD, these events are uncommon but warrant dose reduction if they do occur. Folate supplementation reduces the risk of these events without impairing the anti-inflammatory action. In patients with psoriasis treated with methotrexate, hepatic damage is common; however, among patients with IBD and rheumatoid arthritis, the risk is significantly lower. Renal insufficiency may increase risk of hepatic accumulation and toxicity."
        },
        {
            "id": "InternalMed_Harrison_4049",
            "title": "InternalMed_Harrison",
            "content": "CAuSES of ALoPECiA I. Nonscarring alopecia A. Primary cutaneous disorders 1. 2. 3. 4. 5. B. Drugs C. Systemic diseases 1. 2. 3. 4. 5. 6. Deficiencies of protein, biotin, zinc, and perhaps iron II. A. 1. 2. 3. 4. 5. B. Systemic diseases 1. Discoid lesions in the setting of systemic lupus erythematosusb 2. 3. a Most patients with trichotillomania, pressure-induced alopecia, or early stages of traction alopecia. b While the majority of patients with discoid lesions have only cutaneous disease, these lesions do represent one of the 11 American College of Rheumatology criteria (1982) for systemic lupus erythematosus. c Can involve underlying muscles and osseous structures. of the secondary stage of syphilis. Diffuse thinning of the hair is also 355 associated with hypothyroidism and hyperthyroidism (Table 72-4)."
        },
        {
            "id": "Pharmacology_Katzung_4098",
            "title": "Pharmacology_Katzung",
            "content": "Shima Y et al: The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology (Oxford) 2010;49:2408. Smolen J et al: Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomized controlled trial. Ann Rheum Dis 2009;68:797. Spies CM et al: Prednisone chronotherapy. Clin Exp Rheumatol 2011; 29(Suppl 68):5. Strober B et al: Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment. Br J Dermatol 2013;169:5. Tanaka T, Ogata A, Narazaki M: Tocilizumab for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol 2010;6:6. Teng GG, Turkiewicz AM, Moreland LW: Abatacept: A costimulatory inhibitor for treatment of rheumatoid arthritis. Expert Opin Biol Ther 2005;5:1245."
        },
        {
            "id": "Pharmacology_Katzung_4029",
            "title": "Pharmacology_Katzung",
            "content": "A low incidence of newly formed dsDNA antibodies and antinuclear antibodies (ANAs) has been documented when using TNF-\u03b1\u2013blocking agents, but clinical lupus is extremely rare and the presence of ANA and dsDNA antibodies per se does not contraindicate the use of TNF-\u03b1\u2013blocking agents. In patients with borderline or overt heart failure (HF), TNF-\u03b1\u2013blocking agents can exacerbate HF. TNF-\u03b1\u2013blocking agents can induce the immune system to develop antidrug antibodies in about 17% of cases. These antibodies may interfere with drug efficacy and correlate with infusion site reactions. Injection site reactions occur in 20\u201340% of patients, although they rarely result in discontinuation of therapy. Cases of alopecia areata, hypertrichosis, and erosive lichen planus have been reported. Cutaneous pseudo-lymphomas are reported rarely with TNF-\u03b1\u2013blocking agents, especially infliximab. TNF-\u03b1\u2013blocking agents may increase the risk of gastrointestinal ulcers and large bowel perforation including"
        },
        {
            "id": "InternalMed_Harrison_25254",
            "title": "InternalMed_Harrison",
            "content": "Tofacitinib Tofacitinib is a small-molecule inhibitor that primarily inhibits JAK1 and JAK3, which mediate signaling of the receptors for the common \u03b3-chain-related cytokines IL-2, -4, -7, -9, -15, and -21 as well as IFN-\u03b3 and IL-6. These cytokines all play roles in promoting T and B cell activation as well as inflammation. Tofacitinib, an oral agent, has been shown in randomized, placebo-controlled clinical trials to improve the signs and symptoms of RA significantly over placebo. Major adverse events include elevated serum transaminases indicative of liver injury, neutropenia, increased cholesterol levels, and elevation in serum creatinine. Its use is also associated with an increased risk of infections. Tofacitinib can be used as mono-therapy or in combination with methotrexate. APPROACH TO THE PATIENT:"
        },
        {
            "id": "InternalMed_Harrison_6455",
            "title": "InternalMed_Harrison",
            "content": "Chemotherapeutic agents vary widely in causing alopecia, with anthracyclines, alkylating agents, and topoisomerase inhibitors reliably causing near-total alopecia when given at therapeutic doses. Antimetabolites are more variably associated with alopecia. Psychological support and the use of cosmetic resources are to be encouraged, and \u201cchemo caps\u201d that reduce scalp temperature to decrease the degree of alopecia should be discouraged, particularly during treatment with curative intent of neoplasms, such as leukemia or lymphoma, or in adjuvant breast cancer therapy. The richly vascularized scalp can certainly harbor micrometastatic or disseminated disease."
        },
        {
            "id": "InternalMed_Harrison_4285",
            "title": "InternalMed_Harrison",
            "content": "Drug-Induced Hair Disorders \u2022 dRUg-INdUCEd HAIR LOSS Medications may affect hair follicles at two different phases of their growth cycle: anagen (growth) or telogen (resting). Anagen effluvium occurs within days of drug administration, especially with antimetabolite or other chemotherapeutic drugs. In contrast, in telogen effluvium, the delay is 2 to 4 months following initiation of a new medication. Both present as diffuse nonscarring alopecia most often reversible after discontinuation FIguRE 74-1 Pseudoporphyria due to nonsteroidal anti-inflammatory drugs. FIguRE 74-2 Warfarin necrosis."
        },
        {
            "id": "Psichiatry_DSM-5_1288",
            "title": "Psichiatry_DSM-5",
            "content": "Psychotic disorder. Individuals with a psychotic disorder may remove hair in response to a delusion or hallucination. Trichotillomania is not diagnosed in such cases. Another medical condition. Trichotillomania is not diagnosed if the hair pulling or hair loss is attributable to another medical condition (e.g., in\ufb02ammation of the skin 01\u2018 other der- matological conditions). Other causes of scarring alopecia (e.g., alopecia areata, androgenic alopecia, telogen ef\ufb02uvium) or nonscarring alopecia (e.g., chronic discoid lupus erythema- tosus, lichen planopilaris, central centrifugal cicatricial alopecia, pseudopelade, folliculitis decalvans, dissecting folliculitis, acne keloidalis nuchae) should be considered in individu- als with hair loss who deny hair pulling. Skirt biopsy or dermoscopy can be used to differ- entiate individuals with trichotillomania from those with dermatological disorders."
        },
        {
            "id": "InternalMed_Harrison_26741",
            "title": "InternalMed_Harrison",
            "content": "The features described above are the consequence of thyroid hormone deficiency. However, autoimmune hypothyroidism may be associated with signs or symptoms of other autoimmune diseases, particularly vitiligo, pernicious anemia, Addison\u2019s disease, alopecia areata, and type 1 diabetes mellitus. Less common associations include celiac disease, dermatitis herpetiformis, chronic active hepatitis, rheumatoid arthritis, systemic lupus erythematosus (SLE), myasthenia gravis, and Sj\u00f6gren\u2019s syndrome. Thyroid-associated ophthalmopathy, which usually occurs in Graves\u2019 disease (see below), occurs in about 5% of patients with autoimmune hypothyroidism."
        },
        {
            "id": "Pharmacology_Katzung_3997",
            "title": "Pharmacology_Katzung",
            "content": "4. Adverse Effects: Diarrhea occurs in approximately 25% of patients given leflunomide, although only about 3\u20135% of patients discontinue the drug because of this side effect. Elevation in liver enzymes can occur. Both effects can be reduced by decreasing the dose of leflunomide. Other adverse effects associated with leflunomide are mild alopecia, weight gain, and increased blood pressure. Leukopenia and thrombocytopenia occur rarely. This drug is contraindicated in pregnancy. Methotrexate, a synthetic nonbiologic antimetabolite, is the first-line csDMARD for treating RA and is used in 50\u201370% of patients. It is active in this condition at much lower doses than those needed in cancer chemotherapy (see Chapter 54). 1."
        },
        {
            "id": "Pharmacology_Katzung_6761",
            "title": "Pharmacology_Katzung",
            "content": "TABLE 61\u20132 Biologic agents for psoriasis. moderate severity. Improvement of psoriasis is generally noted following 2 weeks of therapy, with continued improvement for up to 8 weeks of treatment. However, fewer than 10% of patients demonstrate total clearing while on calcipotriene as single-agent therapy. Adverse effects include burning, itching, and mild irritation, with dryness and erythema of the treatment area. Care should be taken to avoid facial contact, which may cause ocular irritation. A once-daily two-compound ointment (Taclonex) or foam (Enstilar) containing calcipotriene and betamethasone dipropionate are available. This combination is more effective than its individual ingredients and is well tolerated, with a safety profile similar to betamethasone dipropionate."
        },
        {
            "id": "Pharmacology_Katzung_4547",
            "title": "Pharmacology_Katzung",
            "content": "5. Other\u2014In addition to the above effects, a number of other adverse reactions have been reported for which a causal relation has not been established. These include alopecia, erythema multiforme, erythema nodosum, and other skin disorders. These drugs are contraindicated in patients with thrombophlebitis, thromboembolic phenomena, and cardiovascular and cerebrovascular disorders or a past history of these conditions. They should not be used to treat vaginal bleeding when the cause is unknown. They should be avoided in patients with known or suspected tumors of the breast or other estrogen-dependent neoplasms. Since these preparations have caused aggravation of preexisting disorders, they should be avoided or used with caution in patients with liver disease, asthma, eczema, migraine, diabetes, hypertension, optic neuritis, retrobulbar neuritis, or convulsive disorders."
        },
        {
            "id": "InternalMed_Harrison_4405",
            "title": "InternalMed_Harrison",
            "content": "(Figs. 76e-1 to 76e-19) While most of these common inflammatory skin diseases and benign neoplastic and reactive lesions usually present as a predominantly dermatologic process, underlying systemic associations may be found in some settings. Atopic dermatitis is often present in patients with an atopic diathesis, including asthma or sinusitis. Psoriasis ranges from limited patches on the elbows and knees to severe erythrodermic and pustular involvement and associated psoriatic arthritis. Some patients with alopecia areata may have an underlying thyroid abnormality requiring screening. Finally, even acne vulgaris, one of the most common inflammatory dermatoses, can be associated with a systemic process such as polycystic ovarian syndrome."
        },
        {
            "id": "Pharmacology_Katzung_4036",
            "title": "Pharmacology_Katzung",
            "content": "2. Pharmacokinetics: The recommended dose of tofacitinib in the treatment of RA is 5 mg twice daily; there is a clear trend to increased response (and increased toxicity) at double this dose. In 2016, the FDA approved extended-release (XR) tofacitinib citrate 11 mg tablets for once-daily treatment. Tofacitinib has an absolute oral bioavailability of 74%, high-fat meals do not affect the AUC, and the elimination half-life is about 3 hours. Metabolism (of 70%) occurs in the liver, mainly by CYP3A4 and to a lesser extent by CYP2C19. The remaining 30% is excreted unchanged by the kidneys. Patients taking CYP enzyme inhibitors and those with moderate hepatic or renal impairment require dose reduction to 5 mg once daily. It should not be given to patients with severe hepatic disease. 3."
        },
        {
            "id": "InternalMed_Harrison_25083",
            "title": "InternalMed_Harrison",
            "content": "Infection, VZV infection, bone marrow suppression, leukopenia, anemia, thrombocytopenia, hemorrhagic cystitis (less with IV), carcinoma of the bladder, alopecia, nausea, diarrhea, malaise, malignancy, ovarian and testicular failure. Ovarian failure is probably not a problem with low dose. Infection, leukopenia, anemia, thrombocytopenia, lymphoma, lymphoproliferative disorders, malignancy, alopecia, cough, diarrhea, fever, GI symptoms, headache, hypertension, hypercholesterolemia, hypokalemia, insomnia, peripheral edema, elevated liver enzymes, tremor, rash Infection, VZV infection, bone marrow suppression, leukopenia, anemia, thrombocytopenia, pancreatitis, hepatotoxicity, malignancy, alopecia, fever, flulike illness, GI symptoms Infusion reactions, allergy, infections probable Infection (including PML), infusion reactions, headache, arrhythmias, allergic responses bIndicates the medication has been used with glucocorticoids in the trials showing efficacy."
        },
        {
            "id": "InternalMed_Harrison_22986",
            "title": "InternalMed_Harrison",
            "content": "Tofacitinib is an oral inhibitor of Janus kinases 1, 3, and, to a lesser extent, 2. It is expected to block signaling involving common gamma chain\u2013containing cytokines including IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. These cytokines are integral to lymphocyte activation, function, and proliferation. It is effective in moderate to severe UC in clinical trials."
        },
        {
            "id": "Surgery_Schwartz_2434",
            "title": "Surgery_Schwartz",
            "content": "tremor, and seizures, also have been reported.29Cyclosporine has several undesirable cosmetic effects, including hirsutism and gingival hyperplasia. It is associated with a higher incidence of hypertension and hyperlipidemia than is tacrolimus.TacrolimusThe calcineurin inhibitor tacrolimus (Prograf) is now the back-bone of most immunosuppressive regimens. Tacrolimus acts by binding FKBPs, causing roughly 10 to 100 times more potent inhibition of IL-2 production than cyclosporine (which acts by binding cyclophilins). It can be given intravenously, orally, or sublingually to maintain trough levels of 8 to 12 ng/mL for the first 3 months posttransplant; then it can be tapered to 6 to 10 ng/mL. The metabolism of tacrolimus is via the cytochrome P450 system, resulting in many significant drug interactions (see Table 11-4).Tacrolimus causes a higher incidence of new-onset dia-betes posttransplant than does cyclosporine. Other side effects include alopecia, nephrotoxicity, neurotoxicity,"
        },
        {
            "id": "Pharmacology_Katzung_6751",
            "title": "Pharmacology_Katzung",
            "content": "Most patients with cystic acne respond to 1\u20132 mg/kg, given in two divided doses daily for 4\u20135 months. If severe cystic acne persists following this initial treatment, after a period of 2 months, a second course of therapy may be initiated. Common adverse effects resemble hypervitaminosis A and include dryness and itching of the skin and mucous membranes. Less common side effects are headache, corneal opacities, pseudotumor cerebri, inflammatory bowel disease, anorexia, alopecia, and muscle and joint pains. These effects are all reversible on discontinuance of therapy. Skeletal hyperostosis has been observed in patients receiving isotretinoin with premature closure of epiphyses noted in children treated with this medication. Lipid abnormalities (triglycerides, high-density lipoproteins) are frequent; their clinical relevance is unknown at present."
        },
        {
            "id": "First_Aid_Step2_1224",
            "title": "First_Aid_Step2",
            "content": "Pityriasis rosea. Alopecia areata (an autoimmune process). Pityriasis versicolor. Asymmetry, border irregularity, color variation, and large diameter. Actinic keratosis. Lesions of 1\u00b0 varicella. Seborrheic dermatitis. Treat with antifungals. Acne vulgaris. A painful, recurrent vesicular eruption of mucocutaneous surfaces. In\ufb02ammation and epithelial thinning of the anogenital area, predominantly in postmenopausal women. Exophytic nodules on the skin with varying degrees of scaling or ulceration; the second most common type of skin cancer. Herpes simplex. Lichen sclerosus. Squamous cell carcinoma. Bias introduced into a study when a clinician is aware of the patient\u2019s treatment type. Bias introduced when screening detects a disease earlier and thus lengthens the time from diagnosis to death."
        },
        {
            "id": "InternalMed_Harrison_4070",
            "title": "InternalMed_Harrison",
            "content": "The differential diagnosis of localized hypomelanosis includes the following primary cutaneous disorders: idiopathic guttate hypomelanosis, postinflammatory hypopigmentation, tinea (pityriasis) versicolor, vitiligo, chemicalor drug-induced leukoderma, nevus depigmentosus (see below), and piebaldism (Table 72-10). In this group of diseases, the areas of involvement are macules or patches with a decrease or absence of pigmentation. Patients with vitiligo also have an increased incidence of several autoimmune disorders, including Hashimoto\u2019s thyroiditis, Graves\u2019 disease, pernicious anemia, Addison\u2019s disease, uveitis, alopecia areata, chronic mucocutaneous candidiasis, and the autoimmune polyendocrine syndromes (types I and II). Diseases of the thyroid gland are the most frequently associated disorders, occurring in up to 30% of patients with vitiligo. Circulating autoantibodies are often found, and the most common ones are antithyroglobulin, antimicrosomal, and antithyroid-stimulating"
        },
        {
            "id": "Pharmacology_Katzung_4097",
            "title": "Pharmacology_Katzung",
            "content": "\u00d8rum M et al: Beneficial effect of infliximab on refractory sarcoidosis. Dan Med J 2012;59:12. Papoutsaki M et al: Infliximab in psoriasis and psoriatic arthritis. BioDrugs 2013;27(Suppl 1):13. Plosker G, Croom K: Sulfasalazine: A review of its use in the management of rheumatoid arthritis. Drugs 2006;65:1825. Riese RJ, Krishnaswami S, Kremer J: Inhibition of JAK kinases in patients with rheumatoid arthritis: Scientific rationale and clinical outcomes. Best Pract Res Clin Rheumatol 2010;24:4. Ruperto N et al: Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008; 2:372. Scott DL, Kingsley GH: Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 2006;355:704. Shima Y et al: The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology (Oxford) 2010;49:2408."
        }
    ],
    "scores": [
        0.0325007868867518,
        0.026967997123336928,
        0.023296421458513114,
        0.0228209084916402,
        0.022350478130481525,
        0.02228606030896993,
        0.02183330688003585,
        0.02173220114239086,
        0.021493003101710775,
        0.021383944190961734,
        0.02044384954832716,
        0.020318502642071315,
        0.02030730306568867,
        0.019327731092436976,
        0.018265221017514596,
        0.018070818070818073,
        0.017786561264822136,
        0.01776565735322783,
        0.017593297791317596,
        0.017523809523809525,
        0.017523722069176614,
        0.017475579975579976,
        0.0169996929188507,
        0.01689664883131512,
        0.01675099138520443,
        0.016129032258064516,
        0.01593726283835062,
        0.01582512315270936,
        0.0158125,
        0.015674908316573997,
        0.015669515669515667,
        0.01565940787863959
    ]
}